Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01952119 · ClinicalTrials.gov registry record · NA

Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care System

A NA study of Hypertension, sponsored by Kaiser Permanente.

Completed
Registry status
NA
Development phase
182
Enrollment target
1
Study location

NCT01952119: Completed NA study of Hypertension, sponsored by Kaiser Permanente.

NCT01952119 is a NA study of Hypertension that has completed, run by Kaiser Permanente. The registered enrollment target is 182 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01952119, a NA study of Hypertension, has completed, sponsored by Kaiser Permanente.

COMPLETED
Registry status
NA
Development phase
182 participants
Enrollment target
1
Study location

Study Summary

This study will assess whether adding a secure message reminder to routine care improves the percentage of patients who complete a follow-up appointment with a new, documented blood pressure reading.

Primary Outcome

Percentage of patients who complete an appointment with a new documented blood pressure reading within six weeks after distributing the secure message reminder

Conditions Studied

Interventions

  • OTHER Secure message reminder

Study Locations (1)

Georgia

  • Kaiser Permanente Georgia - Atlanta

Trial Details

FieldValue
Enrollment Target 182 participants
Start Date 2011-10
Est. Completion 2012-06
Phase NA
Kaiser Permanente

294 total trials

What the finished NCT01952119 record still lists

NCT01952119 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Secure message reminder is the first listed.

NCT01952119 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT01952119 about?

NCT01952119 is a clinical study titled "Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care System". This study will assess whether adding a secure message reminder to routine care improves the percentage of patients who complete a follow-up appointment with a new, documented blood pressure reading.

What is the current status of trial NCT01952119?

This trial is currently completed. It is a NA study. The enrollment target is 182 participants. The study started on 2011-10. Estimated completion is 2012-06.

What conditions does trial NCT01952119 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT01952119?

The interventions under investigation include: Secure message reminder (OTHER).

Who is sponsoring clinical trial NCT01952119?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01952119 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01952119's enrollment target sits among peer trials

182 229th of 470 higher than 242 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03897998 · 182 participants · Phase 2

    Neural Correlates of Hypoalgesia Driven by Observation

  • NCT04300556 · 182 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  • NCT04323735 · 182 participants · Phase 2

    Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

  • NCT05606731 · 182 participants · NA

    Family Intervention to Prevent Childhood Obesity

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01952119, the US trial registry maintained by the National Library of Medicine. NCT01952119 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.